The Merkin Institute for Transformative Technologies will fund early-stage development of novel technological approaches to treating disease
RenalytixAI will assess its lead product, the AI-enabled kidney disease diagnostic KidneyIntelX, in more than 3,500 patients with Type II diabetes through a collaboration...
Biocept and University of California San Diego (UCSD) Medical Center will assess the company’s Target Selector assay in NSCLC patients
Tracking treatment trends is important as more women are receiving genetic testing when they are diagnosed with early-stage breast cancer and treatment options are expanding.
A new study suggests that all young people with newly diagnosed Type 1 diabetes should be tested for a genetic mutation that could be...
Seegene said it will partner Allplex™ assay with Thermo Fisher Scientific’s PCR System, aiming to create a comprehensive MDx solution
The Explify platform is designed to identify more than 50,000 microorganisms, and more than 3,000 known common and rare pathogens. The platform uses a proprietary database of curated DNA and RNA reference sequences to identify 35,000+ viruses, 13,000+ bacteria, 4,000+ fungi, and 150+ parasites.
Company will use single-cell sequencing to find cells playing key roles in disease, and identify genes causing those cells to malfunction
Using the MinION sequencer, the ultra-long reads allow researchers to close 12 gaps in the reference genome though accuracy issues remain
The PGx guide, available in the U.S., will report on an individual's anticipated drug response, metabolism and medication efficacy